ComplianceOnline

FDA Biosimilars Draft Guidance - Scientific Considerations in Demonstrating Biosimilarity to a Reference Product

  • By: www.fda.gov
  • Date: March 16, 2012
Webinar All Access Pass Subscription Abstract:

On February 9, 2012, the U.S FDA released draft guidelines about scientific and quality considerations in bio-similar product development. These guidelines provide insight into the procedures which are required to show high similarity with an FDA-licensed biological product and provide an overview of FDA’s approach in determining bio-similarity of a biologic product.

Bookmark and Share
Best Sellers
You Recently Viewed
    Loading